2024-03-012025-02-282025-02-28false08396213Maxivision Eyecare Ltd2025-10-1686900falseiso4217:GBPxbrli:pure083962132024-02-29083962132025-02-28083962132024-03-012025-02-28083962132023-02-28083962132024-02-29083962132023-03-012024-02-2908396213bus:SmallEntities2024-03-012025-02-2808396213bus:AuditExempt-NoAccountantsReport2024-03-012025-02-2808396213bus:AbridgedAccounts2024-03-012025-02-2808396213bus:PrivateLimitedCompanyLtd2024-03-012025-02-2808396213core:WithinOneYear2025-02-2808396213core:AfterOneYear2025-02-2808396213core:WithinOneYear2024-02-2908396213core:AfterOneYear2024-02-2908396213core:ShareCapital2025-02-2808396213core:SharePremium2025-02-2808396213core:RevaluationReserve2025-02-2808396213core:OtherReservesSubtotal2025-02-2808396213core:RetainedEarningsAccumulatedLosses2025-02-2808396213core:ShareCapital2024-02-2908396213core:SharePremium2024-02-2908396213core:RevaluationReserve2024-02-2908396213core:OtherReservesSubtotal2024-02-2908396213core:RetainedEarningsAccumulatedLosses2024-02-2908396213core:LandBuildings2025-02-2808396213core:PlantMachinery2025-02-2808396213core:Vehicles2025-02-2808396213core:FurnitureFittings2025-02-2808396213core:OfficeEquipment2025-02-2808396213core:NetGoodwill2025-02-2808396213core:IntangibleAssetsOtherThanGoodwill2025-02-2808396213core:ListedExchangeTraded2025-02-2808396213core:UnlistedNon-exchangeTraded2025-02-2808396213core:LandBuildings2024-02-2908396213core:PlantMachinery2024-02-2908396213core:Vehicles2024-02-2908396213core:FurnitureFittings2024-02-2908396213core:OfficeEquipment2024-02-2908396213core:NetGoodwill2024-02-2908396213core:IntangibleAssetsOtherThanGoodwill2024-02-2908396213core:ListedExchangeTraded2024-02-2908396213core:UnlistedNon-exchangeTraded2024-02-2908396213core:LandBuildings2024-03-012025-02-2808396213core:PlantMachinery2024-03-012025-02-2808396213core:Vehicles2024-03-012025-02-2808396213core:FurnitureFittings2024-03-012025-02-2808396213core:OfficeEquipment2024-03-012025-02-2808396213core:NetGoodwill2024-03-012025-02-2808396213core:IntangibleAssetsOtherThanGoodwill2024-03-012025-02-2808396213core:ListedExchangeTraded2024-03-012025-02-2808396213core:UnlistedNon-exchangeTraded2024-03-012025-02-2808396213core:MoreThanFiveYears2024-03-012025-02-2808396213core:Non-currentFinancialInstruments2025-02-2808396213core:Non-currentFinancialInstruments2024-02-2908396213dpl:CostSales2024-03-012025-02-2808396213dpl:DistributionCosts2024-03-012025-02-2808396213core:LandBuildings2024-03-012025-02-2808396213core:PlantMachinery2024-03-012025-02-2808396213core:Vehicles2024-03-012025-02-2808396213core:FurnitureFittings2024-03-012025-02-2808396213core:OfficeEquipment2024-03-012025-02-2808396213dpl:AdministrativeExpenses2024-03-012025-02-2808396213core:NetGoodwill2024-03-012025-02-2808396213core:IntangibleAssetsOtherThanGoodwill2024-03-012025-02-2808396213dpl:GroupUndertakings2024-03-012025-02-2808396213dpl:ParticipatingInterests2024-03-012025-02-2808396213dpl:GroupUndertakingscore:ListedExchangeTraded2024-03-012025-02-2808396213core:ListedExchangeTraded2024-03-012025-02-2808396213dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-03-012025-02-2808396213core:UnlistedNon-exchangeTraded2024-03-012025-02-2808396213dpl:CostSales2023-03-012024-02-2908396213dpl:DistributionCosts2023-03-012024-02-2908396213core:LandBuildings2023-03-012024-02-2908396213core:PlantMachinery2023-03-012024-02-2908396213core:Vehicles2023-03-012024-02-2908396213core:FurnitureFittings2023-03-012024-02-2908396213core:OfficeEquipment2023-03-012024-02-2908396213dpl:AdministrativeExpenses2023-03-012024-02-2908396213core:NetGoodwill2023-03-012024-02-2908396213core:IntangibleAssetsOtherThanGoodwill2023-03-012024-02-2908396213dpl:GroupUndertakings2023-03-012024-02-2908396213dpl:ParticipatingInterests2023-03-012024-02-2908396213dpl:GroupUndertakingscore:ListedExchangeTraded2023-03-012024-02-2908396213core:ListedExchangeTraded2023-03-012024-02-2908396213dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-03-012024-02-2908396213core:UnlistedNon-exchangeTraded2023-03-012024-02-2908396213core:NetGoodwill2025-02-2808396213core:IntangibleAssetsOtherThanGoodwill2025-02-2808396213core:LandBuildings2025-02-2808396213core:PlantMachinery2025-02-2808396213core:Vehicles2025-02-2808396213core:FurnitureFittings2025-02-2808396213core:OfficeEquipment2025-02-2808396213core:AfterOneYear2025-02-2808396213core:WithinOneYear2025-02-2808396213core:ListedExchangeTraded2025-02-2808396213core:UnlistedNon-exchangeTraded2025-02-2808396213core:ShareCapital2025-02-2808396213core:SharePremium2025-02-2808396213core:RevaluationReserve2025-02-2808396213core:OtherReservesSubtotal2025-02-2808396213core:RetainedEarningsAccumulatedLosses2025-02-2808396213core:NetGoodwill2024-02-2908396213core:IntangibleAssetsOtherThanGoodwill2024-02-2908396213core:LandBuildings2024-02-2908396213core:PlantMachinery2024-02-2908396213core:Vehicles2024-02-2908396213core:FurnitureFittings2024-02-2908396213core:OfficeEquipment2024-02-2908396213core:AfterOneYear2024-02-2908396213core:WithinOneYear2024-02-2908396213core:ListedExchangeTraded2024-02-2908396213core:UnlistedNon-exchangeTraded2024-02-2908396213core:ShareCapital2024-02-2908396213core:SharePremium2024-02-2908396213core:RevaluationReserve2024-02-2908396213core:OtherReservesSubtotal2024-02-2908396213core:RetainedEarningsAccumulatedLosses2024-02-2908396213core:NetGoodwill2023-02-2808396213core:IntangibleAssetsOtherThanGoodwill2023-02-2808396213core:LandBuildings2023-02-2808396213core:PlantMachinery2023-02-2808396213core:Vehicles2023-02-2808396213core:FurnitureFittings2023-02-2808396213core:OfficeEquipment2023-02-2808396213core:AfterOneYear2023-02-2808396213core:WithinOneYear2023-02-2808396213core:ListedExchangeTraded2023-02-2808396213core:UnlistedNon-exchangeTraded2023-02-2808396213core:ShareCapital2023-02-2808396213core:SharePremium2023-02-2808396213core:RevaluationReserve2023-02-2808396213core:OtherReservesSubtotal2023-02-2808396213core:RetainedEarningsAccumulatedLosses2023-02-2808396213core:AfterOneYear2024-03-012025-02-2808396213core:WithinOneYear2024-03-012025-02-2808396213core:Non-currentFinancialInstrumentscore:CostValuation2024-03-012025-02-2808396213core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-012025-02-2808396213core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-012025-02-2808396213core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-012025-02-2808396213core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-012025-02-2808396213core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-012025-02-2808396213core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-012025-02-2808396213core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-012025-02-2808396213core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-012025-02-2808396213core:Non-currentFinancialInstrumentscore:CostValuation2025-02-2808396213core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-02-2808396213core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-02-2808396213core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-02-2808396213core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-02-2808396213core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-02-2808396213core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-02-2808396213core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-02-2808396213core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-02-2808396213core:Non-currentFinancialInstrumentscore:CostValuation2024-02-2908396213core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-02-2908396213core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-02-2908396213core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-02-2908396213core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-02-2908396213core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-02-2908396213core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-02-2908396213core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-02-2908396213core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-02-2908396213bus:Director12024-03-012025-02-2808396213bus:Director22024-03-012025-02-28

Maxivision Eyecare Ltd

Registered Number
08396213
(England and Wales)

Unaudited Financial Statements for the Year ended
28 February 2025

Maxivision Eyecare Ltd
Company Information
for the year from 1 March 2024 to 28 February 2025

Directors

K Choda
V Reddappachar

Company Secretary

V Reddappacher

Registered Address

5 School Sike
Carlisle
CA3 0FX

Registered Number

08396213 (England and Wales)
Maxivision Eyecare Ltd
Balance Sheet as at
28 February 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Intangible assets38,57310,716
Tangible assets43,1223,673
Investments113,500-
125,19514,389
Current assets
Stocks4501,750
Debtors2,94111,692
Cash at bank and on hand2,0861,673
5,47715,115
Creditors amounts falling due within one year(28,540)(19,707)
Net current assets (liabilities)(23,063)(4,592)
Total assets less current liabilities102,1329,797
Creditors amounts falling due after one year(82,464)(9,037)
Provisions for liabilities(162)(172)
Net assets19,506588
Capital and reserves
Called up share capital11
Profit and loss account19,505587
Shareholders' funds19,506588
The financial statements were approved and authorised for issue by the Board of Directors on 16 October 2025, and are signed on its behalf by:
K Choda
Director
Registered Company No. 08396213
Maxivision Eyecare Ltd
Notes to the Financial Statements
for the year ended 28 February 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.
Amortisation
Intangible assets are stated at cost less accumulated amortisation and any accumulated impairment losses. Amortisation is provided on a straight-line basis to allocate the cost of the assets over their estimated useful lives, reflecting the pattern in which the asset’s economic benefits are consumed by the company.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)Straight line (years)
Plant and machinery15-
Fixtures and fittings15-
Office Equipment-4
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
Stocks and work in progress
Inventories are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
2.Average number of employees

20252024
Average number of employees during the year22
3.Intangible assets

Total

£
Cost or valuation
At 01 March 2410,716
At 28 February 2510,716
Amortisation and impairment
Charge for year2,143
At 28 February 252,143
Net book value
At 28 February 258,573
At 29 February 2410,716
4.Tangible fixed assets

Total

£
Cost or valuation
At 01 March 2414,820
At 28 February 2514,820
Depreciation and impairment
At 01 March 2411,147
Charge for year551
At 28 February 2511,698
Net book value
At 28 February 253,122
At 29 February 243,673